Chemotherapy: Open Access
Open Access

Gerhard Pütz

Biography

Dr.Gerhard Pütz,co-founder of the company TellTargeting and scientist at the Freiburg University Medical Centre, compares doxorubicin therapy with flying blind.In 2001, Pütz and his colleague Dr.Jürgen Eckes founded the company TellTargeting as a private partnership (German: GbR) and in 2002 they filed a patent for their invention.Dr Gerhard Pütz has over 73 peer reviewed publications.Dr Gerhard Pütz has reviewed for many journals and is currently on the editorial board for Chemotherapy: Open Access.Dr Gerhard Pütz research interests include CARL – and Kinetic Targeting: How to diminish side effects of anticancer drug delivery, Pharmacokinetics and body distribution of particle based anticancer drugs, Therapeutic drug monitoring during chemotherapy.

Research Interest

CARL – and Kinetic Targeting: How to diminish side effects of anticancer drug delivery, Pharmacokinetics and body distribution of particle based anticancer drugs, Therapeutic drug monitoring during chemotherapy.

Relevant Topics